What is the guideline‑directed medical therapy for an adult with symptomatic systolic heart failure (ejection fraction ≤40%)?

Guideline-Directed Medical Therapy for Symptomatic Systolic Heart Failure (EF ≤40%)

For adults with symptomatic heart failure and ejection fraction ≤40%, initiate all four foundational medication classes—ACE inhibitor (or ARNI), beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor—along with diuretics for congestion, as this combination provides the greatest mortality and morbidity reduction. 1

Core Pharmacologic Pillars (The "Fantastic Four")

The evidence overwhelmingly supports simultaneous use of four medication classes that each independently reduce mortality by ≥20% 1:

1. Renin-Angiotensin System Inhibition

• ACE inhibitors are first-line therapy for all patients with reduced left ventricular systolic function 1
• Start with low doses and uptitrate to target doses used in clinical trials 1
• Sacubitril/valsartan (ARNI) should replace ACE inhibitors in ambulatory patients who remain symptomatic despite optimal therapy with ACE inhibitor, beta-blocker, and MRA 1
• ARNI provides superior mortality reduction compared to ACE inhibitors alone and reduces sudden death risk 1
• ARBs are reserved for patients intolerant of ACE inhibitors 1

Practical initiation: Review diuretic dosing first, avoid excessive diuresis for 24 hours before starting, and consider evening dosing to minimize hypotension 1

2. Evidence-Based Beta-Blockers

• Only three beta-blockers have proven mortality benefit: carvedilol, metoprolol succinate, and bisoprolol 1
• Initiate in addition to ACE inhibitor for all stable symptomatic patients 1
• These agents reduce sudden cardiac death risk, which cannot be delayed even in clinically stable patients 1
• Start at low doses and uptitrate to target doses from landmark trials 1

3. Mineralocorticoid Receptor Antagonists (MRA)

• Add spironolactone or eplerenone for patients who remain symptomatic despite ACE inhibitor and beta-blocker 1
• MRAs provide ≥20% mortality reduction and reduce sudden death 1
• Monitor potassium and renal function closely; avoid in patients with significant renal dysfunction or hyperkalemia 1
• In post-MI patients with EF <40% and diabetes or heart failure, aldosterone blockade is Class I recommendation 1

4. SGLT2 Inhibitors

• Initiate regardless of diabetes status 1, 2
• These agents reduce heart failure hospitalizations and cardiovascular mortality 1, 3
• Can be started early, even during hospitalization 4, 5
• The evidence base continues to strengthen, making these essential foundational therapy 1

Symptomatic Management

Diuretics for Congestion

• Essential when fluid overload manifests as pulmonary congestion or peripheral edema 1
• Loop diuretics provide rapid improvement in dyspnea and exercise tolerance 1
• Always combine with ACE inhibitors when possible 1
• For hospitalized patients with significant fluid overload, start intravenous loop diuretics immediately in the emergency department—early intervention improves outcomes 1
• Initial IV dose should equal or exceed chronic oral daily dose 1
• If inadequate diuresis occurs, intensify with higher loop diuretic doses, add second diuretic (metolazone, spironolactone, IV chlorothiazide), or use continuous loop diuretic infusion 1

Additional Therapies for Specific Populations

Hydralazine-Isosorbide Dinitrate

• For self-identified African American patients with NYHA class III-IV who remain symptomatic on ACE inhibitor/ARB, beta-blocker, and MRA 1
• This combination may be inferior to ACE inhibitors for mortality in broader populations 1

Device Therapy Considerations

• ICD for primary prevention in patients with EF ≤35%, NYHA class II-III symptoms, on optimal medical therapy for ≥3 months, expected survival >1 year with good functional status 1
• Not recommended within 40 days of MI 1
• CRT for patients in sinus rhythm with QRS ≥150 msec, LBBB morphology, EF ≤35%, and symptomatic despite GDMT 1

Critical Implementation Strategy

The "forced-titration" approach from landmark trials is essential but rarely followed in practice 1:

• Start at low doses but aggressively uptitrate at planned intervals to target doses
• Asymptomatic vital sign or laboratory changes should not prevent uptitration 1
• If medications are discontinued or doses reduced, these should be temporary events—reinstitute and achieve target doses 1
• Most patients in clinical practice receive only starting doses indefinitely, which has unproven mortality benefit 1

Common Pitfalls to Avoid

• Do not use diltiazem or verapamil—they increase heart failure worsening and hospitalizations 1
• Avoid triple renin-angiotensin system blockade (ACE inhibitor + ARB + MRA or renin inhibitor)—increased risk of renal dysfunction and hyperkalemia 1
• Do not delay GDMT initiation in newly diagnosed patients—most eligible patients should receive beta-blockers and ACE inhibitors/ARBs/ARNIs within the first 3 months 6, 7
• Hospitalization is an opportunity—use admission to optimize all four medication classes before discharge, as this reduces 30-day readmissions in a dose-dependent manner 4, 8, 5

Monitoring Requirements

• Daily weights at the same time 1
• Fluid intake/output during active diuresis 1
• Daily electrolytes, BUN, and creatinine during IV diuretics or active medication titration 1
• Serial assessment of congestion signs and symptoms 1

Patient Education Essentials

• Explain what heart failure is and why symptoms occur 1
• Teach symptom recognition and when to seek care 1
• Emphasize medication adherence importance 1
• Sodium restriction when necessary (severe heart failure) 1
• Avoid excessive fluid intake in severe HF 1
• Smoking cessation with nicotine replacement 1
• Encourage daily physical activity in stable patients to prevent deconditioning 1

The Reality Gap

Despite clear guidelines, real-world implementation remains suboptimal 6, 9, 7:

• Within 3 months of diagnosis, only 93% receive RASI/ARNI, 92% receive beta-blockers, 35% receive MRA, and 26% receive SGLT2i 6
• Older patients with more comorbidities (atrial fibrillation, COPD, prior stroke, dementia) receive less GDMT 9
• Referral to heart failure clinic independently increases GDMT initiation across all medication classes (HR 1.54-2.49) 7
• Each additional GDMT class at discharge reduces 30-day readmission risk progressively, with 4 GDMT classes showing HR 0.56 compared to 1 class 8